Preclinical characterization of a novel investigational monoclonal antibody CM313 with potent CD38-positive cell killing activity
Introduction: CM313 is currently under clinical investigation for treatments of multiple myeloma, systemic lupus erythematosus, and immune thrombocytopenia.